Dashboard
Manage Tickers

JNJJOHNSON & JOHNSON

NYSE jnj.com


$ 164.41 $ -0.61 (-0.37 %)    

Friday, 06-Sep-2024 15:59:57 EDT
CLICK TO SEE RELEVANT LITIGATION UPDATES
Y-mAbs Therapeutics, Inc. | YMAB | Take Action!
QQQ $ 446.25 $ -12.35 (-2.68 %)
DIA $ 404.28 $ -3.99 (-0.98 %)
SPY $ 539.90 $ -9.25 (-1.68 %)
TLT $ 99.49 $ -0.01 (-0.01 %)
GLD $ 230.65 $ -1.72 (-0.74 %)
$ 164.38
$ 164.39 x 100
-- x --
-- - --
$ 140.50 - $ 168.85
6,016,884
na
395.7B
$ 0.47
$ 10.41
TBD
na
na ($ 0.03)
na
TBD na
How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In
# Filing Date Period End Date Type Report Link
1 07-25-2024 06-30-2024 10-Q
2 05-01-2024 03-31-2024 10-Q
3 02-16-2024 12-31-2023 10-K
4 10-27-2023 10-01-2023 10-Q
5 10-27-2023 10-01-2023 10-Q
6 07-31-2023 07-02-2023 10-Q
7 04-28-2023 04-02-2023 10-Q
8 02-16-2023 01-01-2023 10-K
9 10-27-2022 10-02-2022 10-Q
10 07-29-2022 07-03-2022 10-Q
11 04-29-2022 04-03-2022 10-Q
12 02-17-2022 01-02-2022 10-K
13 10-29-2021 10-03-2021 10-Q
14 07-29-2021 07-04-2021 10-Q
15 04-30-2021 04-04-2021 10-Q
16 02-22-2021 01-03-2021 10-K
17 10-23-2020 09-27-2020 10-Q
18 07-24-2020 06-28-2020 10-Q
19 04-29-2020 03-29-2020 10-Q
20 02-18-2020 12-29-2019 10-K
21 10-28-2019 09-29-2019 10-Q
22 07-29-2019 06-30-2019 10-Q
23 05-01-2019 03-31-2019 10-Q
24 02-20-2019 12-30-2018 10-K
25 10-31-2018 09-30-2018 10-Q
26 08-02-2018 07-01-2018 10-Q
27 05-01-2018 04-01-2018 10-Q
28 02-21-2018 12-31-2017 10-K
29 11-02-2017 10-01-2017 10-Q
30 08-03-2017 07-02-2017 10-Q
31 05-08-2017 04-02-2017 10-Q
32 02-27-2017 01-01-2017 10-K
33 11-04-2016 10-02-2016 10-Q
34 08-04-2016 07-03-2016 10-Q
35 05-10-2016 04-03-2016 10-Q
36 02-24-2016 01-03-2016 10-K
37 10-30-2015 09-27-2015 10-Q
38 07-31-2015 06-28-2015 10-Q
39 05-01-2015 03-29-2015 10-Q
40 02-24-2015 12-28-2014 10-K
Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In
# Date Analyst Firm Upside/Downside Price Target Change Rating Change Current Rating

News

OPINIONS

reported-sunday-johnson--johnson-unveils-long-term-data-from-mariposa-study-showing-rybrevant-plus-lazcluze-outperforming-osimertinib-in-lung-cancer-treatment
Reported Sunday, Johnson & Johnson Unveils...
09/09/2024 07:26:53

New longer-term data from the MARIPOSA study confirm superior outcomes of chemotherapy-free RYBREVANT® plus LAZCLUZE™ regimen...

dell-costar-paypal-and-a-major-health-care-stock-on-cnbcs-final-trades
Dell, CoStar, PayPal And A Major Health Ca...
09/06/2024 12:47:00

Bill Baruch of Blue Line Capital named Dell Technologies Inc. his "final trade" on CNBC's "Halftime Report."

wall-streets-most-accurate-analysts-weigh-in-on-3-health-care-stocks-with-over-3-dividend-yields
Wall Street's Most Accurate Analysts Weigh...
09/06/2024 12:21:22

johnson--johnson-raises-talc-settlement-offer-to-9b-moves-closer-to-settlement-victory
Johnson & Johnson Raises Talc Settlement O...
09/05/2024 18:30:04

Johnson & Johnson boosts talc settlement offer to $9 billion, gaining support from key lawyer Allen Smith for quicker claim...

Core News & Articles
CNBC Halftime Report Final Trades: PayPal,...
09/05/2024 17:02:43

psychedelic-drugs-market-set-to-grow-by-137b-by-2028-driven-by-mental-health-disorders-and-ai-integration
Psychedelic Drugs Market Set To Grow By $1...
09/05/2024 16:53:46

The global psychedelic drugs market is projected to grow by USD 1.37 billion by 2028, driven by mental health needs and AI adva...

johnson--johnson-wins-over-longtime-holdout-for-talc-settlement-tort-lawyer-allen-smith-now-backs-jjs-settlement-plan-after-the-company-raised-its-offer-to-roughly-9b-sources-say---wsj
"Johnson & Johnson Wins Over Longtime Hold...
09/04/2024 20:12:26

https://www.wsj.com/articles/johnson-johnson-wins-over-longtime-holdout-for-talc-settlement-0db573d7?page=1 Johnson & Johns...

court-orders-johnson--johnson-to-compensate-auris-health-shareholders-1b
Court Orders Johnson & Johnson To Compensa...
09/04/2024 18:12:58

Johnson & Johnson is ordered to pay $1 billion in damages to Auris Health shareholders for breaching a 2019 merger agreemen...

delaware-judge-rules-johnson--johnson-owes-auris-health-inc-1b-in-damages-over-2019-health-robot-deal
Delaware Judge Rules Johnson & Johnson Owe...
09/04/2024 14:53:56

- Reuters 

despite-medicare-negotiations-americans-may-still-have-to-pay-more-for-prescription-drugs
Despite Medicare Negotiations, Americans M...
09/03/2024 19:12:09

Despite Medicare's first-ever negotiated drug prices under the Inflation Reduction Act, U.S. costs remain significantly hig...

critical-insights-from-johnson--johnson-analyst-ratings-what-you-need-to-know
Critical Insights From Johnson & Johnson A...
09/03/2024 16:00:52

cantor-fitzgerald-reiterates-overweight-on-johnson--johnson-maintains-215-price-target
Cantor Fitzgerald Reiterates Overweight on...
09/03/2024 14:01:28

Cantor Fitzgerald analyst Louise Chen reiterates Johnson & Johnson (NYSE:JNJ) with a Overweight and maintains $215 price...

johnson--johnson-spin-off-kenvue-wins-lawsuit-over-pain-killer-tylenol-rapid-release-gelcaps
Johnson & Johnson-Spin Off Kenvue Wins Law...
08/30/2024 17:47:55

Kenvue defends against a consumer lawsuit alleging that its Tylenol "Rapid Release" gelcaps did not relieve pain faster...

johnson--johnsons-golden-cross-a-bullish-prescription-for-investors
Johnson & Johnson's Golden Cross: A Bullis...
08/29/2024 19:18:57

Johnson & Johnson (NYSE:JNJ) achieves Golden Cross, signaling shift to bullish trend. Stock at $164.43, above all key movin...

johnson--johnson-seeks-fda-approval-for-muscle-weakness-drug-and-gears-up-showdown-with-argenx-and-ucb
Johnson & Johnson Seeks FDA Approval For M...
08/29/2024 16:29:10

Johnson & Johnson has submitted a Biologics License Application (BLA) to the FDA for nipocalimab, seeking its first global ...

competitor-analysis-evaluating-johnson-amp-johnson-and-competitors-in-pharmaceuticals-industry
Competitor Analysis: Evaluating Johnson &a...
08/29/2024 15:00:51

johnson--johnson-seeks-first-approval-of-nipocalimab-to-treat-broadest-population-living-with-antibody-positive-generalized-myasthenia-gravis
Johnson & Johnson Seeks First Approval Of ...
08/29/2024 12:13:29

Marks first FDA submission for nipocalimab, an investigational treatment that binds with high affinity and specificity to block...

aha-urges-hrsa-to-take-immediate-enforcement-action-to-block-jjs-illegal-imposition-of-340b-rebate-model---american-hospital-association
'AHA Urges HRSA To Take Immediate Enforcem...
08/28/2024 17:33:51

https://www.aha.org/news/headline/2024-08-28-aha-urges-hrsa-take-immediate-enforcement-action-block-jjs-illegal-imposition-340b...

spotlight-on-johnson--johnson-analyzing-the-surge-in-options-activity
Spotlight on Johnson & Johnson: Analyzing ...
08/28/2024 17:31:03

johnson-johnson-partner-addex-therapeutics-selects-investigational-compound-for-substance-use-disorder
Johnson Johnson-Partner Addex Therapeutics...
08/27/2024 12:48:04

Addex Therapeutics stock surged after announcing clinical candidate selection with Indivior for substance use disorder treatmen...

CORE & Plaid

CORE & Plaid

CORE Finalist

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION